{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:20Z","timestamp":1740138500965,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12032-021-01571-1","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T08:02:46Z","timestamp":1630137766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy"],"prefix":"10.1007","volume":"38","author":[{"given":"Nilgun","family":"Karasu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilal","family":"Akalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuriye","family":"Gokce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulbaki","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikail","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hande","family":"Kulak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhat","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffer","family":"Keklik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-4611","authenticated-orcid":false,"given":"Munis","family":"Dundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"issue":"3","key":"1571_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019br\u0131en S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164\u201372.","journal-title":"N Engl J Med"},{"issue":"4","key":"1571_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322.","journal-title":"Blood"},{"issue":"4","key":"1571_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2478\/folmed-2018-0030","volume":"60","author":"AJ Linev","year":"2018","unstructured":"Linev AJ, Ivanov HJ, Zhelyazkov IG, Ivanova H, Goranova-Marinova VS, Stoyanova VK. Mutations associated with imatinib mesylate resistance\u2014review. Folia Med (Plovdiv). 2018;60(4):617\u201323.","journal-title":"Folia Med (Plovdiv)"},{"key":"1571_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00833","volume":"9","author":"B Izzo","year":"2019","unstructured":"Izzo B, Gottardi EM, Errichiello S, Daraio F, Barat\u00e8 C, Galimberti S. Monitoring chronic myeloid leukemia: how molecular tools may drive therapeutic approaches. Front Oncol. 2019;9:1\u201312.","journal-title":"Front Oncol"},{"issue":"S2","key":"1571_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/HS9.0000000000000254","volume":"3","author":"O Hantschel","year":"2019","unstructured":"Hantschel O. Chronic myeloid leukemia. HemaSphere. 2019;3(S2):47.","journal-title":"HemaSphere"},{"issue":"2","key":"1571_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","volume":"249","author":"JV Melo","year":"2007","unstructured":"Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 2007;249(2):121\u201332.","journal-title":"Cancer Lett"},{"issue":"5","key":"1571_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11899-019-00543-7","volume":"14","author":"M Yaghmaie","year":"2019","unstructured":"Yaghmaie M, Yeung CC. Molecular mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep. 2019;14(5):395\u2013404.","journal-title":"Curr Hematol Malig Rep"},{"issue":"24","key":"1571_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20246141","volume":"20","author":"L Bavaro","year":"2019","unstructured":"Bavaro L, Martelli M, Cavo M, Soverini S. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci. 2019;20(24):1\u201323.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1571_CR9","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1002\/cam4.2410","volume":"8","author":"G Etienne","year":"2019","unstructured":"Etienne G, Dulucq S, Huguet F, Schmitt A, Lascaux A, Hayette S, et al. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Med. 2019;8(11):5173\u201382.","journal-title":"Cancer Med"},{"issue":"5","key":"1571_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201323.","journal-title":"Genet Med"},{"issue":"1","key":"1571_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-016-0108-0","volume":"35","author":"ZJ Kang","year":"2016","unstructured":"Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, et al. The philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35(1):1\u201315.","journal-title":"Chin J Cancer"},{"issue":"1","key":"1571_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276\u201383.","journal-title":"Blood"},{"issue":"12","key":"1571_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00277-006-0171-8","volume":"85","author":"Y Wei","year":"2006","unstructured":"Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, et al. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Ann Hematol. 2006;85(12):841\u20137.","journal-title":"Ann Hematol"},{"issue":"3","key":"1571_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/hon.2721","volume":"38","author":"SH Chien","year":"2020","unstructured":"Chien SH, Liu HM, Chen PM, Ko PS, Lin JS, Chen YJ, et al. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors. Hematol Oncol. 2020;38(3):390\u20138.","journal-title":"Hematol Oncol"},{"issue":"10","key":"1571_CR15","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Rosti G, Soverini S. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia. 2019;33(10):2358\u201364. https:\/\/doi.org\/10.1038\/s41375-019-0562-1.","journal-title":"Leukemia"},{"issue":"2","key":"1571_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","volume":"20","author":"FX Mahon","year":"2014","unstructured":"Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20(2):310\u201322.","journal-title":"Clin Cancer Res"},{"key":"1571_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","volume":"11","author":"M Alikian","year":"2017","unstructured":"Alikian M, Gale RP, Apperley JF, Foroni L, Alikian M. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif. 2017;11:4\u201320. https:\/\/doi.org\/10.1016\/j.bdq.2017.01.001.","journal-title":"Biomol Detect Quantif"},{"issue":"4","key":"1571_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1080\/10428194.2019.1691196","volume":"61","author":"R El Fakih","year":"2019","unstructured":"El Fakih R, Chaudhri N, Alfraih F, Rausch CR, Naqvi K, Jabbour E. Complexity of chronic-phase CML management after failing a second-generation TKI. Leuk Lymphoma. 2019;61(4):776\u201387.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1571_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","volume":"141","author":"K Machova Polakova","year":"2015","unstructured":"Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887\u201399.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Supplement_1","key":"1571_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/blood-2019-125108","volume":"134","author":"H de Lavallade","year":"2019","unstructured":"de Lavallade H, Jackson S, Kizilors A, Etienne G, Huguet F, Guerci-Bresler A, et al. Prospective evaluation of ABL kinase domain mutational analysis by next-generation-sequencing in newly diagnosed CP CML patients undergoing first-line treatment with nilotinib alone or nilotinib + pegylated interferon-\u03b12a in a prospective phase III trial. Blood. 2019;134(Supplement_1):664\u2013664.","journal-title":"Blood"},{"issue":"1","key":"1571_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0686-1","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol. 2019;12(1):1\u201311.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1571_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2019002969","volume":"135","author":"S Soverini","year":"2020","unstructured":"Soverini S, Bavaro L, de Benedittis C, Martelli M, Iurlo A, Orofino N, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood. 2020;135(8):534\u201341.","journal-title":"Blood"},{"issue":"2","key":"1571_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bjh.17301","volume":"193","author":"S Soverini","year":"2021","unstructured":"Soverini S, Martelli M, Bavaro L, De Benedittis C, Papayannidis C, Sartor C, et al. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2021;193(2):271\u20139.","journal-title":"Br J Haematol"},{"issue":"2","key":"1571_CR24","first-page":"2419","volume":"15","author":"B Ko\u00e7kan","year":"2018","unstructured":"Ko\u00e7kan B, Topta\u015f T, Atag\u00fcnd\u00fcz I, Tu\u011flular AT, \u00d6zer A, Akkiprik M. Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia. Oncol Lett. 2018;15(2):2419\u201324.","journal-title":"Oncol Lett"},{"issue":"4","key":"1571_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342.","journal-title":"Cancer Cell"},{"issue":"11","key":"1571_CR26","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018\u201329.","journal-title":"Lancet Oncol"},{"key":"1571_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.mgene.2018.05.003","volume":"17","author":"NA Azad","year":"2018","unstructured":"Azad NA, Shah ZA, Pandith AA, Rasool R, Rasool JA, Baba SM, et al. Analysis of ABL kinase domain mutations as a probable cause of imatinib resistance in chronic myeloid leukemia patients of Kashmir. Meta Gene. 2018;17:93\u20138. https:\/\/doi.org\/10.1016\/j.mgene.2018.05.003.","journal-title":"Meta Gene"},{"issue":"1\u20132","key":"1571_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drup.2007.02.002","volume":"10","author":"T Fojo","year":"2007","unstructured":"Fojo T. Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updates. 2007;10(1\u20132):59\u201367.","journal-title":"Drug Resist Updates"},{"issue":"4","key":"1571_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2174\/1389450117666160615074120","volume":"18","author":"D Perrotti","year":"2016","unstructured":"Perrotti D, Silvestri G, Stramucci L, Yu J, Trotta R. Cellular and molecular networks in chronic myeloid leukemia: the leukemic stem, progenitor and stromal cell interplay. Curr Drug Targets. 2016;18(4):377\u201388.","journal-title":"Curr Drug Targets"},{"key":"1571_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","volume":"2009","author":"D Bixby","year":"2009","unstructured":"Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program. 2009;2009:461\u201376.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"1571_CR31","first-page":"70","volume":"40","author":"M Gorre","year":"2019","unstructured":"Gorre M, Sashidhar R, Annamaneni S, Digumarti R, et al. Demographic and clinical characteristics of chronic myeloid leukemia patients: a study on confined populations of southern India. Indian J Med Paediatr Oncol. 2019;40(1):70\u20136.","journal-title":"Indian J Med Paediatr Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01571-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T03:38:37Z","timestamp":1632713917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01571-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved with the decision dated Dec 16th, 2020 and numbered 629 by Erciyes University Clinical Research Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants gave written informed consent in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"120"}}